

Ref.: NLL/CS/2025-451

January 20, 2025

To

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

2. BSE Limited
Corporate Relationship
Department, P J Towers, Dalal
Street, Mumbai 400 001

Scrip Code: 532649

Sub: Regulation 30 of the Securities and Exchange of Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and as amended by Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024

Dear Sir/ Madam,

This is with reference to point no. 1 of Annexure 1 of letter no. NLL/CS/2024-416 dated October 15, 2024, vide which the Company had informed pending Litigation(s) as required under Regulation 30 of the LODR Regulations.

Pursuant to captioned regulations, please find enclosed herewith necessary disclosures in prescribed format for details/ updation of Litigation and/ or orders passed by any regulatory authority or judicial body as per Annexure-A.

The relevant extract of letter no. NLL/CS/2024-416 dated October 15, 2024, is attached as an Annexure B.

This is for your information and record please.

Thanking you,

Yours faithfully,
For **Nectar Lifesciences Limited**

(Neha Vaishnav)
Company Secretary & Compliance Officer

Encl.: as above

The Details of Litigation and/ or order passed by regulatory authority or judicial body for or against Nectar Lifesciences Limited (“Company”)

Updation			
Sr no.	Brief details of litigation and action taken or order passed	Expected Financial Implication	Quantum of claims, if any
1.	Nectar Lifesciences Limited		
	Name of Opposite Party: Principal Commissioner of Income Tax (Central), Gurugram	Tax relief against the claim of Rs. 3,58,36,864/- has been provided by Delhi High Court as it has dismissed the appeal of Income Tax Department.	NIL
	Date of Order: January 14, 2025 Date of receipt of Order: January 20, 2025		
	Brief Detail of the Case: Tax relief of Rs.3,58,36,864/- (on dividend income received from subsidiary company in Sri Lanka) given by Income Tax Appellant Tribunal (“ITAT”), Chandigarh, for FY 2005-06, had been challenged by Income Tax Department in Hon’ble Delhi High Court.		
	Delhi High Court, vide its order dated 14.01.2025, has dismissed the appeal of Income Tax Department for AY 2005-06, on merit.		
	The formal order of Court is uploaded on its website on January 20, 2025.		

The Details of Litigation and/ or order passed by regulatory authority or judicial body for or against Nectar Lifesciences Limited (“Company”)

At the time of becoming party			
Sr no.	Brief details of litigation and action taken or order passed	Expected Financial Implication	Quantum of claims, if any
.....			
1.	<p>Nectar Lifesciences Limited</p> <p>Name of Opposite Party: Principal Commissioner of Income Tax (Central), Gurugram</p> <p>Forum where Pending: Hon’ble Delhi High Court</p> <p>Brief Detail of the Case: Tax relief of Rs.3,58,36,864/- (on dividend income received from subsidiary company in Sri Lanka) given by Income Tax Appellant Tribunal (“ITAT”), Chandigarh, for FY 2005-06, has been challenged by Income Tax Department in Hon’ble Delhi High Court. The above relief was allowed by the ITAT Chandigarh on the basis of judgement of Hon’ble Supreme Court in the case of Torquoise Investment & Finance Ltd. vs. DCIT.</p> <p>Date of hearing is fixed for 16.10.2024.</p> <p>We became aware of this case on 15.10.2024 suo-moto without receipt of any notice from Delhi High Court.</p>	<p>Expected financial implication will be Rs.3,58,36,864/- if Hon’ble Delhi High Court decides against the Company.</p>	<p>As disclosed in financial implications column.</p>